{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T09:59:32Z","timestamp":1771667972813,"version":"3.50.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-025-04516-0","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T07:26:47Z","timestamp":1769066807000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multifocal papillary thyroid carcinoma: the impact of multifocality metrics on the response to treatment"],"prefix":"10.1007","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0177-939X","authenticated-orcid":false,"given":"Alfredo","family":"Campenn\u00ec","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Martini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Petranovic Ovcaricek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosaria Maddalena","family":"Ruggeri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Nicocia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Alibrandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Capoccetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Zuccal\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Minutoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Fadda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Giovanella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"4516_CR1","doi-asserted-by":"crossref","unstructured":"1. Campenn\u00ec A, Giovanella L. Nuclear medicine therapy of thyroid cancer post-thyroidectomy. In: Sathekge M, Luster M, eds. Nuclear Medicine and Molecular Imaging. Vol 4. Elsevier; 2022:42\u201355. doi:10.1016\/B978-0-12-822960-6.00202-7","DOI":"10.1016\/B978-0-12-822960-6.00202-7"},{"key":"4516_CR2","doi-asserted-by":"crossref","unstructured":"2. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7\u201333. doi:10.3322\/CAAC.21654,","DOI":"10.3322\/caac.21654"},{"key":"4516_CR3","doi-asserted-by":"crossref","unstructured":"3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11\u201330. doi:10.3322\/CAAC.21166,","DOI":"10.3322\/caac.21166"},{"key":"4516_CR4","doi-asserted-by":"crossref","unstructured":"4. Giovanella L, Treglia G, Verburg FA, Salvatori M, Ceriani L. Serum cytokeratin 19 fragments: A dedifferentiation marker in advanced thyroid cancer. Eur J Endocrinol. 2012;167(6):793\u2013797. doi:10.1530\/EJE-12-0660,","DOI":"10.1530\/EJE-12-0660"},{"key":"4516_CR5","doi-asserted-by":"crossref","unstructured":"5. Campenn\u00ec A, Giovanella L, Pignata SA, et al. Thyroid remnant ablation in differentiated thyroid cancer: searching for the most effective radioiodine activity and stimulation strategy in a real-life scenario. Nucl Med Commun. 2015;36(11):1100\u20131106. doi:10.1097\/MNM.0000000000000367","DOI":"10.1097\/MNM.0000000000000367"},{"key":"4516_CR6","doi-asserted-by":"crossref","unstructured":"6. Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988\u20132005. Cancer. 2009;115(16):3801\u20133807. doi:10.1002\/CNCR.24416,","DOI":"10.1002\/cncr.24416"},{"key":"4516_CR7","doi-asserted-by":"crossref","unstructured":"7. Li M, Maso LD, Vaccarella S. Global trends in thyroid cancer incidence and the impact of overdiagnosis. Lancet Diabetes Endocrinol. 2020;8(6):468\u2013470. doi:10.1016\/S2213-8587(20)30115-7","DOI":"10.1016\/S2213-8587(20)30115-7"},{"key":"4516_CR8","doi-asserted-by":"crossref","unstructured":"8. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973\u20132002. J Am Med Assoc. 2006;295(18):2164\u20132167. doi:10.1001\/JAMA.295.18.2164,","DOI":"10.1001\/jama.295.18.2164"},{"key":"4516_CR9","doi-asserted-by":"crossref","unstructured":"9. Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R. Worldwide increasing incidence of thyroid cancer: Update on epidemiology and risk factors. J Cancer Epidemiol. 2013;2013. doi:10.1155\/2013\/965212,","DOI":"10.1155\/2013\/965212"},{"key":"4516_CR10","doi-asserted-by":"crossref","unstructured":"10. Dal Maso L, Vaccarella S, Franceschi S. Trends in thyroid cancer incidence and overdiagnosis in the USA. Lancet Diabetes Endocrinol. 2025;13(3):167\u2013169. doi:10.1016\/S2213-8587(24)00343-7","DOI":"10.1016\/S2213-8587(24)00343-7"},{"key":"4516_CR11","doi-asserted-by":"crossref","unstructured":"11. Kent WDT, Hall SF, Isotalo PA, Houlden RL, George RL, Groome PA. Increased incidence of differentiated thyroid carcinoma and detection of subclinical disease. CMAJ. 2007;177(11):1357\u20131361. doi:10.1503\/CMAJ.061730","DOI":"10.1503\/cmaj.061730"},{"key":"4516_CR12","doi-asserted-by":"crossref","unstructured":"12. Miranda-Filho A, Lortet-Tieulent J, Bray F, et al. Thyroid cancer incidence trends by histology in 25 countries: a population-based study. Lancet Diabetes Endocrinol. 2021;9(4):225\u2013234. doi:10.1016\/S2213-8587(21)00027-9","DOI":"10.1016\/S2213-8587(21)00027-9"},{"key":"4516_CR13","doi-asserted-by":"crossref","unstructured":"13. Carling T, Udelsman R. Thyroid cancer. Annu Rev Med. 2014;65:125\u2013137. doi:10.1146\/ANNUREV-MED-061512-105739,","DOI":"10.1146\/annurev-med-061512-105739"},{"key":"4516_CR14","doi-asserted-by":"crossref","unstructured":"14. Dal Maso L, Lise M, Zambon P, et al. Incidence of thyroid cancer in Italy, 1991\u20132005: Time trends and age-period-cohort effects. Annals of Oncology. 2011;22(4):957\u2013963. doi:10.1093\/annonc\/mdq467","DOI":"10.1093\/annonc\/mdq467"},{"key":"4516_CR15","doi-asserted-by":"crossref","unstructured":"15. Seib CD, Sosa JA. Evolving Understanding of the Epidemiology of Thyroid Cancer. Endocrinol Metab Clin North Am. 2019;48(1):23\u201335. doi:10.1016\/j.ecl.2018.10.002","DOI":"10.1016\/j.ecl.2018.10.002"},{"key":"4516_CR16","doi-asserted-by":"crossref","unstructured":"16. Sanabria A, Kowalski LP, Shah JP, et al. Growing incidence of thyroid carcinoma in recent years: Factors underlying overdiagnosis. Head Neck. 2018;40(4):855\u2013866. doi:10.1002\/HED.25029,","DOI":"10.1002\/hed.25029"},{"key":"4516_CR17","doi-asserted-by":"crossref","unstructured":"17. Suteau V, Munier M, Briet C, Rodien P. Sex bias in differentiated thyroid cancer. Int J Mol Sci. 2021;22(23). doi:10.3390\/IJMS222312992,","DOI":"10.3390\/ijms222312992"},{"key":"4516_CR18","doi-asserted-by":"crossref","unstructured":"18. Campenn\u00ec A, Giovanella L, Siracusa M, et al. Is malignant nodule topography an additional risk factor for metastatic disease in low-risk differentiated thyroid cancer? Thyroid. 2014;24(11):1607\u20131611. doi:10.1089\/THY.2014.0217","DOI":"10.1089\/thy.2014.0217"},{"key":"4516_CR19","doi-asserted-by":"crossref","unstructured":"19. Gallicchio R, Giacomobono S, Capacchione D, et al. Should patients with remnants from thyroid microcarcinoma really not be treated with iodine-131 ablation? Endocrine. 2013;44(2):426\u2013433. doi:10.1007\/S12020-013-9935-9,","DOI":"10.1007\/s12020-013-9935-9"},{"key":"4516_CR20","doi-asserted-by":"crossref","unstructured":"20. Tuttle RM, Tala H, Shah J, et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid. 2010;20(12):1341\u20131349. doi:10.1089\/THY.2010.0178","DOI":"10.1089\/thy.2010.0178"},{"key":"4516_CR21","doi-asserted-by":"crossref","unstructured":"21. Lamartina L, Grani G, Durante C, Borget I, Filetti S, Schlumberger M. Follow-up of differentiated thyroid cancer \u2013 what should (and what should not) be done. Nat Rev Endocrinol. 2018;14(9):538\u2013551. doi:10.1038\/S41574-018-0068-3,","DOI":"10.1038\/s41574-018-0068-3"},{"key":"4516_CR22","doi-asserted-by":"crossref","unstructured":"22. Campenn\u00ec A, Barbaro D, Guzzo M, Capoccetti F, Giovanella L. Personalized management of differentiated thyroid cancer in real life - practical guidance from a multidisciplinary panel of experts. Endocrine. 2020;70(2):280\u2013291. doi:10.1007\/S12020-020-02418-X","DOI":"10.1007\/s12020-020-02418-x"},{"key":"4516_CR23","doi-asserted-by":"crossref","unstructured":"23. Giovanella L, Duntas LH. MANAGEMENT OF ENDOCRINE DISEASE: The role of rhTSH in the management of differentiated thyroid cancer: pros and cons. Eur J Endocrinol. 2019;181(4):R133-R145. doi:10.1530\/EJE-19-0149","DOI":"10.1530\/EJE-19-0149"},{"key":"4516_CR24","doi-asserted-by":"crossref","unstructured":"24. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1-133. doi:10.1089\/THY.2015.0020","DOI":"10.1089\/thy.2015.0020"},{"key":"4516_CR25","doi-asserted-by":"crossref","unstructured":"25. Luster M, Clarke SE, Dietlein M, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35(10):1941\u20131959. doi:10.1007\/s00259-008-0883-1","DOI":"10.1007\/s00259-008-0883-1"},{"key":"4516_CR26","doi-asserted-by":"crossref","unstructured":"26. Zhao Q, Ming J, Liu C, et al. Multifocality and total tumor diameter predict central neck lymph node metastases in papillary thyroid microcarcinoma. Ann Surg Oncol. 2013;20(3):746\u2013752. doi:10.1245\/S10434-012-2654-2,","DOI":"10.1245\/s10434-012-2654-2"},{"key":"4516_CR27","doi-asserted-by":"crossref","unstructured":"27. Tam AA, Ozdemir D, Ogmen BE, et al. Should multifocal papillary thyroid carcinomas classified as T1A with a tumor diameter sum of 1 to 2 centimeters be reclassified as T1B? Endocrine Practice. 2017;23(5):526\u2013535. doi:10.4158\/EP161488.OR","DOI":"10.4158\/EP161488.OR"},{"key":"4516_CR28","doi-asserted-by":"crossref","unstructured":"28. Manso J, Censi S, Roberti A, et al. Prognostic significance of the sum of the diameters of single foci in multifocal papillary thyroid cancer: the concept of new-old tumor burden. Ther Adv Endocrinol Metab. 2020;11. doi:10.1177\/2042018820964326,","DOI":"10.1177\/2042018820964326"},{"key":"4516_CR29","doi-asserted-by":"crossref","unstructured":"29. Jiang KC, Lin B, Zhang Y, Zhao LQ, Luo DC. Total tumor diameter is a better indicator of multifocal papillary thyroid microcarcinoma: A propensity score matching analysis. Front Endocrinol (Lausanne). 2022;13. doi:10.3389\/FENDO.2022.974755,","DOI":"10.3389\/fendo.2022.974755"},{"key":"4516_CR30","doi-asserted-by":"crossref","unstructured":"30. Elbasan O, Ilg\u0131n C, Yavuz DG. Does total tumour diameter, multifocality, number of tumour foci, or laterality predict lymph node metastasis or recurrence in differentiated thyroid cancer? Endokrynol Pol. 2023;74(2):153\u2013167. doi:10.5603\/EP.A2023.0015,","DOI":"10.5603\/EP.a2023.0015"},{"key":"4516_CR31","doi-asserted-by":"crossref","unstructured":"31. Feng JW, Qu Z, Qin AC, Pan H, Ye J, Jiang Y. Significance of multifocality in papillary thyroid carcinoma. European Journal of Surgical Oncology. 2020;46(10):1820\u20131828. doi:10.1016\/j.ejso.2020.06.015","DOI":"10.1016\/j.ejso.2020.06.015"},{"key":"4516_CR32","doi-asserted-by":"crossref","unstructured":"32. Wang W, Su X, He K, et al. Comparison of the clinicopathologic features and prognosis of bilateral versus unilateral multifocal papillary thyroid cancer: An updated study with more than 2000 consecutive patients. Cancer. 2016;122(2):198\u2013206. doi:10.1002\/CNCR.29689,","DOI":"10.1002\/cncr.29689"},{"key":"4516_CR33","doi-asserted-by":"crossref","unstructured":"33. Kim HJ, Sohn SY, Jang HW, Kim SW, Chung JH. Multifocality, but not bilaterality, is a predictor of disease recurrence\/persistence of papillary thyroid carcinoma. World J Surg. 2013;37(2):376\u2013384. doi:10.1007\/S00268-012-1835-2,","DOI":"10.1007\/s00268-012-1835-2"},{"key":"4516_CR34","doi-asserted-by":"crossref","unstructured":"34. Michael Tuttle R, Ahuja S, Avram AM, et al. Controversies, Consensus, and Collaboration in the Use of 131I Therapy in Differentiated Thyroid Cancer: A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association. Thyroid. 2019;29(4):461\u2013470. doi:10.1089\/THY.2018.0597","DOI":"10.1089\/thy.2018.0597"},{"key":"4516_CR35","doi-asserted-by":"crossref","unstructured":"35. Zulewski H, Giovanella L, Bilz S, et al. Multidisciplinary approach for risk-oriented treatment of low-risk papillary thyroid cancer in Switzerland. Swiss Med Wkly. 2019;149:w14700. doi:10.4414\/SMW.2019.14700","DOI":"10.4414\/smw.2019.14700"},{"key":"4516_CR36","doi-asserted-by":"crossref","unstructured":"36. So YK, Kim MW, Son YI. Multifocality and bilaterality of papillary thyroid microcarcinoma. Clin Exp Otorhinolaryngol. 2015;8(2):174\u2013178. doi:10.3342\/CEO.2015.8.2.174,","DOI":"10.3342\/ceo.2015.8.2.174"},{"key":"4516_CR37","doi-asserted-by":"crossref","unstructured":"37. Ng SC, Kuo SF, Chen ST, Hsueh C, Huang BY, Lin J Der. Therapeutic Outcomes of Patients with Multifocal Papillary Thyroid Microcarcinomas and Larger Tumors. Int J Endocrinol. 2017;2017. doi:10.1155\/2017\/4208178,","DOI":"10.1155\/2017\/4208178"},{"key":"4516_CR38","doi-asserted-by":"crossref","unstructured":"38. Kuo SF, Lin SF, Chao TC, Hsueh C, Lin KJ, Lin J Der. Prognosis of multifocal papillary thyroid carcinoma. Int J Endocrinol. 2013;2013. doi:10.1155\/2013\/809382,","DOI":"10.1155\/2013\/809382"},{"key":"4516_CR39","doi-asserted-by":"crossref","unstructured":"39. Niemeier LA, Kuffner Akatsu H, Song C, et al. A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma. Cancer. 2012;118(8):2069\u20132077. doi:10.1002\/CNCR.26425,","DOI":"10.1002\/cncr.26425"},{"key":"4516_CR40","doi-asserted-by":"crossref","unstructured":"40. Giovanella L, Milan L, Roll W, et al. Postoperative thyroglobulin as a yard-stick for radioiodine therapy: decision tree analysis in a European multicenter series of 1317 patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2023;50(9):2767\u20132774. doi:10.1007\/S00259-023-06239-8\/TABLES\/6","DOI":"10.1007\/s00259-023-06239-8"},{"key":"4516_CR41","doi-asserted-by":"crossref","unstructured":"41. Liu C, Wang S, Zeng W, Guo Y, Liu Z, Huang T. Total tumour diameter is superior to unifocal diameter as a predictor of papillary thyroid microcarcinoma prognosis. Sci Rep. 2017;7(1). doi:10.1038\/S41598-017-02165-6,","DOI":"10.1038\/s41598-017-02165-6"},{"key":"4516_CR42","doi-asserted-by":"crossref","unstructured":"42. Kim H, Kwon H, Moon BI. Association of Multifocality with Prognosis of Papillary Thyroid Carcinoma: A Systematic Review and Meta-analysis. JAMA Otolaryngol Head Neck Surg. 2021;147(10):847\u2013854. doi:10.1001\/JAMAOTO.2021.1976.","DOI":"10.1001\/jamaoto.2021.1976"},{"key":"4516_CR43","doi-asserted-by":"crossref","unstructured":"43. Ringel MD, Sosa JA, Baloch Z, et al. 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer. Thyroid. 2025;35(8):841\u2013985. doi:10.1177\/10507256251363120","DOI":"10.1177\/10507256251363120"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04516-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-025-04516-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04516-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T08:59:53Z","timestamp":1771664393000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-025-04516-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4516"],"URL":"https:\/\/doi.org\/10.1007\/s12020-025-04516-0","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author name \"Rosaria Maddalena Ruggeri\" updated to appear as \"Ruggeri RM\" in pubmed","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Conflict of interest Luca Giovanella is Editorial Board member of Endocrine. The authors have no other relevant financial or nonfinancial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}],"article-number":"48"}}